Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTK vs Blood Cardioplegia in CABG
NCT04203680Phase 1Completed
- Sponsor
- Ain Shams University
- Start
- Dec 2019
- Primary completion
- Mar 2020
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HTK Custodiol in coronary artery disease (CAD) (2 arms), sponsored by Ain Shams University. Primary endpoints: Mortality rate at 30 days, Cardiac enzymes at 24 hours and 2 more. Started Dec 2019; status: completed.
02
Drugs
HTK Custodiol
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04203680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203680.